comprehensive -WSS

comprehensive

author：leisure time 2025-09-30 17:45:06 - browse：8

Vir Biotechnology said Thursday that a long-acting antibody drug designed to protect healthy individuals from influenza A failed to do so in a nearly 3,000-person clinical trial.

Volunteers who received the highest dose of the drug, known as VIR-2482, were only 16% less likely than the placebo group to develop symptomatic influenza A infections, as defined by trial criteria, over a seven-month period. The difference was not statistically significant.

The results are a setback in broader efforts to develop better protective measures against both seasonal and potential pandemic influenza strains. In the short term, Vir and outside experts hoped VIR-2482 could provide additional annual protection for at-risk groups like older adults, as flu vaccines are often only modestly effective.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： South Korea throws huge K

Wikipedia

hotspot

WSS

The White House hikes tariffs on plastic syringes made in China

Readout Newsletter: Biogen, Ionis, Johnson & Johnson news

WuXi Biologics execs register to lobby as Congress comes for the company

The best solution to the drug shortages problem

Police still searching for prisoner who escaped from NYC hospital

To spot an incipient stroke, tiny brain probe acts ‘like a microscope’

leisure time

comprehensive

explore

Trump demands the U.S. pay no more for drugs than other countries … again

Ripples from Flovent's discontinuation is killing children with asthma

State Dept. review finds Biden bears some blame for Afghanistan failures

Man killed during FBI raid in connection with threats against Biden, other officials

Sports medicine is finally prioritizing gender equality

Adam's Biotech Scorecard: PDS Biotech's survival benefit is overstated

Malaria cases in Florida and Texas: Here’s what you need to know

American woman, child freed after being kidnapped in Haiti last month

In age of alternative facts, a scholarly course on calling out crap

Police still searching for prisoner who escaped from NYC hospital

hotspot

Oak Street deal isn't the answer to health care's woes

Friends ask where James Watson's attitudes about race came from

Galapagos to make CAR

Adam's Biotech Scorecard: PDS Biotech's survival benefit is overstated

Why H5N1 bird flu is keeping the CDC's top flu scientist awake

Abbott's new stent may help patients with peripheral artery disease

Wikipedia

focus

hotspot

knowledge